Achieve Life Sciences, Inc.
$4.25
▲
2.87%
2026-04-21 05:03:00
www.achievelifesciences.com
NCM: ACHV
Explore Achieve Life Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$226.27 M
Current Price
$4.25
52W High / Low
$6.03 / $1.95
Stock P/E
—
Book Value
$0.4
Dividend Yield
—
ROCE
-167.79%
ROE
-2.58%
Face Value
—
EPS
$-1.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
1.96
Debt / Equity
69.5
Current Ratio
4.39
Quick Ratio
4.39
Forward P/E
-3.36
Price / Sales
—
Enterprise Value
$164.36 M
EV / EBITDA
-3.01
EV / Revenue
—
Rating
None
Target Price
$14.75
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Genprex, Inc. | $1.16 | — | $10.45 M | — | -194.32% | -3.39% | $55 / $1.15 | $3.78 |
| 2. | Indaptus Therapeutics, Inc. | $3.61 | — | $7.74 M | — | -629.32% | -5.88% | $19.91 / $1.51 | $1.45 |
| 3. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 4. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 5. | Xenetic Biosciences, Inc. | $3.4 | — | $7.09 M | — | -38.33% | -40% | $13.93 / $1.9 | $3.23 |
| 6. | PMV Pharmaceuticals, Inc. | $1.43 | — | $73.59 M | — | -81.99% | -55.37% | $1.88 / $0.81 | $1.96 |
| 7. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -14.73 M | -14.69 M | -12.56 M | -12.89 M | -12.19 M | — |
| Net Profit | -14.66 M | -14.44 M | -12.72 M | -12.83 M | -12.36 M | — |
| EPS in Rs | -0.28 | -0.27 | -0.24 | -0.24 | -0.23 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -54.88 M | -39.07 M | -27.25 M | -40.8 M |
| Net Profit | -54.65 M | -39.83 M | -29.82 M | -42.35 M |
| EPS in Rs | -1.03 | -0.75 | -0.56 | -0.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 41.79 M | 38.63 M | 19.37 M | 29.97 M |
| Total Liabilities | 20.27 M | 17.73 M | 20.82 M | 21.67 M |
| Equity | 21.52 M | 20.9 M | -1.45 M | 8.3 M |
| Current Assets | 39.89 M | 36.47 M | 16.98 M | 27.33 M |
| Current Liabilities | 9.08 M | 6.68 M | 20.81 M | 21.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -49.47 M | -29.77 M | -24.48 M | -37.57 M |
| Investing CF | 6.11 M | -21.58 M | -0.02 M | 0 M |
| Financing CF | 51.53 M | 48.53 M | 15.28 M | 19.32 M |
| Free CF | -49.47 M | -29.77 M | -24.5 M | -37.57 M |
| Capex | -0 M | — | -0.02 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -37.21% | -33.58% | 29.6% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.